---
document_datetime: 2025-11-18 10:29:25
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tecentriq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tecentriq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.1105628
conversion_datetime: 2025-12-27 19:54:51.246546
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tecentriq

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 13/11/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000287554                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted   |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000290209 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted                                        | 16/10/2025 | SmPC and PL | SmPC new text Uveitis (frequency uncommon for atezolizumab monotherapy and rare for atezolizumab combination therapy), cytomegalovirus infection (frequency rare), sarcoidosis (frequency rare) arthritis (frequency common) and tenosynovitis (frequency uncommon) have been included in the adverse reaction table in section 4.8 of the SmPC. Uveitis has also been added to the existing warning on immune-mediated adverse reactions in section 4.4 of the SmPC. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted A grouped application comprised of 5 Type II Variations, based on safety reports, as follows: C.I.4: Update of sections 4.4 and 4.8 of the SmPC in order to add 'uveitis' in the warning section and to the list of adverse drug reactions (ADRs). C.I.4: Update of section 4.8 of the SmPC in order to add 'cytomegalovirus infection' to the list of ADRs with frequency 'rare'. C.I.4: Update of   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | 'tenosynovitis' to the list of ADRs with frequency 'uncommon'. C.I.4: Update of section 4.8 of the SmPC in order to add 'arthritis' to the list of ADRs with frequency 'common'. C.I.4: Update of section 4.8 of the SmPC in order to add 'sarcoidosis' to the list of ADRs with frequency 'rare'. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial and formatting changes to the PI, to bring it in line with the latest QRD template.   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000294085 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Minor change in the manufacturing process of a sterile finished product after the primary packaging step - Accepted                                                                                                                                                                                                                      | 23/09/2025 | N/A |
| Variation type II / EMA/VR/0000245126 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.b Substantial change to the manufacturing process of the active substance which may have a significant impact on the quality, safety or efficacy of the medicinal product - Accepted                                                                                                                                                                                                                                   | 24/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000272433   | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted   | 16/06/2025   | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000262253   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.4 of the SmPC in order to amend an existing warning on infusion- related reactions with anaphylaxis based on                                                                                                                                                                                                                                                                                                                             | 05/06/2025   | SmPC and PL | SmPC new text The warning related to infusion- related reactions in Section 4.4 of the SmPC has been updated to include that anaphylaxis has been observed with atezolizumab: Infusion-related reactions have been observed with atezolizumab, including anaphylaxis. This is based on the review of Drug safety reports. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                       | Drug safety report No. 1135433; the Package Leaflet is updated accordingly. The RMP version 32.1 is also agreed. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000245137 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to add ''Peripheral neuropathy'' to the list of adverse drug reactions (ADRs) of atezolizumab monotherapy with frequency ''common'', as well as, to add Immune thrombocytopenia to the existing ADR Thrombocytopenia of atezolizumab monotherapy and combination therapy based on post-marketing data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.4. | 27/03/2025 | SmPC and PL | SmPC new text In section 4.8 of the SmPC: - Peripheral neuropathy has been added as a new ADR to the atezolizumab monotherapy column of the ADR table . -Immune thrombocytopenia has been added as a footnote to further define the existing ADR thrombocytopenia for both atezolizumab monotherapy and in combination of the ADR table. For more information, please refer to the Summary of Product Characteristics. |